
Point Biomedical Corporation Profile last edited on: 1/23/2019
CAGE:
UEI:
Business Identifier: Specialized imaging and drug delivery Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 14
County: San Mateo
Congr. District: 14
County: San Mateo
Public Profile
POINT Biomedical Corporation is a development stage company focusing on novel technologies for the delivery of diagnostic and therapeutic compounds. POINT Biomedical has developed acoustically responsive microspheres using proprietary biomaterial technologies to address two large market opportunities, primarily in the area of cardiology: ultrasound contrast agents and ultrasound targeted drug delivery. biSphere Configuration: Shell within a Shell POINT Biomedical has developed a proprietary hollow microsphere technology platform that is based on a biSphere configuration: a shell within a shell. The inner shell, formed from biodegradable polymers, provides physical structure and controls acoustic response; while the outer layer functions as the biological interface and can provide a scaffold for site-specific targeting ligands. Each layer or shell can be independently modified to fulfill specific application requirements. The core or payload space can be filled with a gas, such as nitrogen, for ultrasound imaging as in our myocardial perfusion agent, CARDIOsphere, or with biotherapeutic agents for drug delivery applications.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2000 | 1 | NIH | $126,958 | |
Project Title: Investigation of a Third Generation Echo-Contrast Agent |
Key People / Management
Tom Feldman -- CEO
Jerry C Griffin -- President
Malcolm Farnsworth -- Executive Vice President of Finance and Chief Financial Officer
Jonathan Goldman -- Vice President of Medical Affairs and Chief Medical Officer
Thomas B Ottoboni -- COO
Jerry C Griffin -- President
Malcolm Farnsworth -- Executive Vice President of Finance and Chief Financial Officer
Jonathan Goldman -- Vice President of Medical Affairs and Chief Medical Officer
Thomas B Ottoboni -- COO
Company News
There are no news available.